Oncology
1845, Edinburgh, Scotland and Berlin, Prussia — simultaneous descriptions by John Hughes Bennett and Rudolf Virchow
Chronic myelogenous leukemia was first described in the mid-nineteenth century by physicians who observed unusual enlargements of the spleen alongside strange alterations in the blood. Early investigators lacked the tools to understand its cellular origins, and for decades it was grouped loosely with other wasting diseases of the blood and lymphatic system. The condition became a landmark in the history of cancer biology when researchers identified a specific chromosomal abnormality associated with it in the twentieth century.
Historical Narrative
The earliest recognizable clinical descriptions of what would later be called chronic myelogenous leukemia emerged in the 1840s, when two physicians working independently made observations that would cement their names in medical history. John Hughes Bennett in Edinburgh and Rudolf Virchow in Berlin both published accounts in 1845 of patients whose blood had turned a peculiar pale or whitish hue and whose spleens had grown to extraordinary sizes. Bennett initially interpreted the phenomenon as a form of suppuration — essentially pus accumulating in the bloodstream — while Virchow argued it represented a distinct pathological entity. Virchow coined the term 'Leukämie,' derived from the Greek words for white and blood, to describe the condition, and his framing ultimately prevailed in medical nomenclature.
Throughout the latter half of the nineteenth century, physicians attempted to categorize leukemia into subtypes based on anatomical observations made during autopsies. The distinction between what was called splenic or myelogenous leukemia and lymphatic leukemia was gradually refined as microscopic techniques improved. Ernst Neumann and Giulio Bizzozero contributed to the understanding that blood cells were produced in the bone marrow, a discovery that helped clarify why the marrow appeared so dramatically altered in affected patients. By the close of the nineteenth century, the myelogenous form was understood to involve an overproduction of a particular lineage of blood cells originating in the marrow, though the reason for this overproduction remained entirely mysterious.
Early therapeutic attempts in the late nineteenth and early twentieth centuries were largely palliative and reflected the profound uncertainty surrounding the disease's cause. Arsenic, in the form of Fowler's solution, had been used empirically for various blood disorders since the eighteenth century, and physicians applied it to leukemia patients with modest and temporary results. The discovery of X-rays by Wilhelm Conrad Röntgen in 1895 opened a new avenue, and within a few years clinicians were directing radiation at enlarged spleens, observing that this sometimes reduced the organ's size and temporarily lowered the abnormal white cell counts. This represented one of the first uses of radiation as a medical intervention, though practitioners of the era had no understanding of why it worked and little awareness of its cumulative dangers.
The twentieth century brought increasingly sophisticated tools to bear on the question of causation. In 1960, Peter Nowell at the University of Pennsylvania and David Hungerford at the Fox Chase Cancer Center made a discovery that transformed not only the understanding of this disease but of cancer biology as a whole. Examining chromosomes from the cells of affected patients, they identified a consistently abnormal, unusually small chromosome that appeared in the malignant cells. This became known as the Philadelphia chromosome, named for the city where it was discovered, and it marked the first time a specific chromosomal abnormality had been consistently linked to a human cancer.
Subsequent decades brought further elucidation of the Philadelphia chromosome's nature. Janet Rowley, working in the early 1970s, demonstrated that the abnormality was not simply a truncated chromosome but the result of a translocation — an exchange of material between two chromosomes. This discovery refined the scientific community's understanding of how genetic disruption could drive malignant transformation and set the stage for molecular investigations that would define the field for the remainder of the twentieth century.
Key Historical Figures
Historical narrative only — this page describes how Chronic myelogenous leukemia was understood historically. It is not medical advice and does not describe current diagnosis or treatment. Sourced from verified medical history references (NIH, Encyclopaedia Britannica, and standard medical history texts). See our medical disclaimer.